Abstract：
Pericardial diseases have gained renewed clinical interest, leading to a renaissance in the field. There have been many recent advances in pericardial diseases in both multimodality cardiac imaging of diagnoses, such as recurrent, transient constrictive and effusive-constrictive pericarditis, and targeted therapeutics, especially anti-interleukin (IL)-1 agents that affect the inflammasome as part of autoinflammatory pathophysiology. There remains a large educational gap for clinicians, leading to variability in evaluation and management of these patients. The latest pericardial imaging (American Society of Echocardiography, European Association of Cardiovascular Imaging) and clinical guidelines (European Society of Cardiology) are >8-10 years of age and may not reflect current practice. Recent clinical trials involving anti-IL-1 agents in recurrent pericarditis, including anakinra (AIRTRIP), rilonacept (RHAPSODY), and goflikicept have demonstrated their efficacy. The present document represents an international position statement from world leaders in the pericardial field, focusing on novel concepts and emphasizing the role of multimodality cardiac imaging as well as new therapeutics in pericardial diseases.
摘要：
心包疾病获得了新的临床兴趣，导致该领域的复兴。心包疾病在诊断的多模态心脏成像方面有许多最新进展，例如经常性的，短暂性缩窄性和渗出性缩窄性心包炎，和靶向治疗，特别是抗白细胞介素（IL）-1药物，影响炎症小体作为自身炎症病理生理学的一部分。临床医生的教育差距仍然很大，导致这些患者的评估和管理存在差异。最新的心包成像（美国超声心动图学会，欧洲心血管成像协会）和临床指南（欧洲心脏病学会）年龄>8-10岁，可能无法反映当前的实践。最近涉及抗IL-1药物治疗复发性心包炎的临床试验，包括阿纳金拉（AIRTRIP），rilonacept(RHAPSODY),和goflikicept已经证明了他们的功效。本文件代表了心包领域世界领导人的国际立场声明，专注于新概念，强调多模态心脏成像以及新的治疗方法在心包疾病中的作用。
